What is the share price of Cohance Lifesciences Ltd (COHANCE) today?
The share price of COHANCE as on 7th May 2026 is ₹486.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Cohance Lifesciences Ltd (COHANCE) share?
The past returns of Cohance Lifesciences Ltd (COHANCE) share are- Past 1 week: -0.46%
- Past 1 month: 57.50%
- Past 3 months: 41.77%
- Past 6 months: -33.52%
- Past 1 year: -57.02%
- Past 3 years: 1.33%
- Past 5 years: -11.23%
What are the peers or stocks similar to Cohance Lifesciences Ltd (COHANCE)?
The peers or stocks similar to Cohance Lifesciences Ltd (COHANCE) include:What is the market cap of Cohance Lifesciences Ltd (COHANCE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cohance Lifesciences Ltd (COHANCE) is ₹18411.04 Cr as of 7th May 2026.What is the 52 week high and low of Cohance Lifesciences Ltd (COHANCE) share?
The 52-week high of Cohance Lifesciences Ltd (COHANCE) is ₹1158.30 and the 52-week low is ₹266.70.What is the PE and PB ratio of Cohance Lifesciences Ltd (COHANCE) stock?
The P/E (price-to-earnings) ratio of Cohance Lifesciences Ltd (COHANCE) is 68.73. The P/B (price-to-book) ratio is 10.00.Which sector does Cohance Lifesciences Ltd (COHANCE) belong to?
Cohance Lifesciences Ltd (COHANCE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Cohance Lifesciences Ltd (COHANCE) shares?
You can directly buy Cohance Lifesciences Ltd (COHANCE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Cohance Lifesciences Ltd
COHANCE Share Price
NSECOHANCE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
COHANCE Performance & Key Metrics
COHANCE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 65.73 | 10.00 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 41.10 | 6.15 | 0.54% |
from 9 analysts
Price Upside
Earnings Growth
Rev. Growth
COHANCE Company Profile
Cohance Lifesciences Limited is a technology-driven CDMO in India, offering custom synthesis, process R&D, and manufacturing services for pharmaceuticals and specialty chemicals.
COHANCE Sentiment Analysis
COHANCE Sentiment Analysis
COHANCE Stock Summary · February 2026
Cohance Lifesciences is navigating a challenging transition year, particularly in its Pharma CDMO segment, where destocking and delays linked to a significant molecule nearing patent expiry have impacted program timelines. Despite these hurdles, the company is witnessing increased engagement from global innovators and has successfully converted a late-stage commercial RFP into a confirmed program, bolstering its robust late-stage pipeline of nine Phase 3 programs. The Specialty Chemicals segment has shown resilience with a 32% year-on-year revenue growth, while the API Plus segment faces regulatory challenges that have led to an 8% revenue decline. Management remains cautiously optimistic about recovery in FY '27, focusing on diversification and strategic partnerships to enhance market positioning and mitigate margin pressures. Overall, while current financial performance reflects volatility, the long-term outlook is supported by a strong pipeline and proactive business development efforts.
COHANCE Stock Growth Drivers
COHANCE Stock Growth Drivers
9Strong Late-Stage Pipeline
The company supports a robust late-stage pipeline with nine Phase 3 programs, providing medium-term visibility
Increased Customer Engagement
There has been a notable increase in customer engagement, particularly with global innovators and large
COHANCE Stock Challenges
COHANCE Stock Challenges
4Revenue Decline and Financial Performance Issues
The company has experienced a significant revenue decline, with a reported 6.7% decrease in revenue
Operational Challenges and Delays
The company is facing operational challenges, including customer-led delays in product reloads and off-take due
COHANCE Forecast
COHANCE Forecasts
Price
Revenue
Earnings
COHANCE Share Price Forecast
COHANCE Share Price Forecast
All values in ₹
All values in ₹
COHANCE Company Revenue Forecast
COHANCE Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
COHANCE Stock EPS (Earnings Per Share) Forecast
COHANCE Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
COHANCE
COHANCE
Income
Balance Sheet
Cash Flow
COHANCE Income Statement
COHANCE Income Statement
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 250.90 | 234.16 | 269.98 | 507.49 | 619.96 | 697.79 | 852.47 | 563.48 | 571.17 | 550.71 | ||||||||||
| Operating & Other expenses | 133.09 | 153.74 | 179.59 | 362.98 | 398.40 | 438.86 | 626.98 | 445.40 | 434.62 | 454.06 | ||||||||||
| EBITDA | 117.81 | 80.42 | 90.39 | 144.51 | 221.56 | 258.93 | 225.49 | 118.08 | 136.55 | 96.65 | ||||||||||
| Depreciation/Amortization | 11.89 | 12.79 | 17.25 | 31.28 | 37.79 | 43.56 | 54.17 | 45.14 | 44.02 | 46.94 | ||||||||||
| PBIT | 105.92 | 67.63 | 73.14 | 113.23 | 183.77 | 215.37 | 171.32 | 72.94 | 92.53 | 49.71 | ||||||||||
| Interest & Other Items | 0.50 | 2.16 | 2.30 | 10.20 | 9.61 | 10.80 | 10.45 | 10.18 | 8.76 | 9.11 | ||||||||||
| PBT | 105.42 | 65.47 | 70.84 | 103.03 | 174.16 | 204.57 | 160.87 | 62.76 | 83.77 | 40.60 | ||||||||||
| Taxes & Other Items | 25.84 | 18.72 | 17.48 | 27.66 | 35.69 | 51.50 | 40.44 | 13.88 | 9.69 | 3.88 | ||||||||||
| Net Income | 79.58 | 46.75 | 53.36 | 75.37 | 138.47 | 153.07 | 120.43 | 48.88 | 74.08 | 36.72 | ||||||||||
| EPS | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 4.02 | 3.16 | 1.28 | 1.94 | 0.96 |
COHANCE Company Updates
Investor Presentation
COHANCE Stock Peers
COHANCE Past Performance & Peer Comparison
COHANCE Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Cohance Lifesciences Ltd | 68.73 | 10.00 | — |
| Sun Pharmaceutical Industries Ltd | 40.62 | 6.12 | 0.86% |
| Torrent Pharmaceuticals Ltd | 77.18 | 19.43 | 0.73% |
| Lupin Ltd | 34.04 | 6.46 | 0.49% |
COHANCE Stock Price Comparison
Compare COHANCE with any stock or ETFCOHANCE Holdings
COHANCE Shareholdings
COHANCE Promoter Holdings Trend
COHANCE Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
A significant proportion of promoter holdings is pledged
COHANCE Institutional Holdings Trend
COHANCE Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
COHANCE Shareholding Pattern
COHANCE Shareholding Pattern
COHANCE Shareholding History
COHANCE Shareholding History
Mutual Funds Invested in COHANCE
Mutual Funds Invested in COHANCE
No mutual funds holding trends are available
Top 5 Mutual Funds holding Cohance Lifesciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0855% | Percentage of the fund’s portfolio invested in the stock 3.18% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/44 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6784% | Percentage of the fund’s portfolio invested in the stock 0.13% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 273/338 (-8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6549% | Percentage of the fund’s portfolio invested in the stock 0.13% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 65/69 (-11) |
Compare 3-month MF holding change on Screener
smallcases containing COHANCE stock
smallcases containing COHANCE stock
Looks like this stock is not in any smallcase yet.
COHANCE Events
COHANCE Events
COHANCE Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
COHANCE Dividend Trend
No dividend trend available
COHANCE Upcoming Dividends
COHANCE Upcoming Dividends
No upcoming dividends are available
COHANCE Past Dividends
COHANCE Past Dividends
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateFeb 15, 2022
Dividend/Share
₹2.00
Ex DateEx Date
Feb 15, 2022
COHANCE Stock News & Opinions
COHANCE Stock News & Opinions
Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 May 2026.
AGI Greenpac Ltd, Black Box Ltd, Electronics Mart India Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 28 April 2026.Cohance Lifesciences Ltd surged 15.30% to Rs 498.9 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 20.16 lakh shares were traded on the counter so far as against the average daily volumes of 5.45 lakh shares in the past one month. AGI Greenpac Ltd spiked 12.13% to Rs 633.05. The stock was the second biggest gainer in 'A' group. On the BSE, 2.77 lakh shares were traded on the counter so far as against the average daily volumes of 15484 shares in the past one month. Black Box Ltd soared 10.24% to Rs 638.75. The stock was the third biggest gainer in 'A' group. On the BSE, 1.94 lakh shares were traded on the counter so far as against the average daily volumes of 20649 shares in the past one month. Electronics Mart India Ltd added 10.00% to Rs 121.5. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.01 lakh shares were traded on the counter so far as against the average daily volumes of 33506 shares in the past one month. Epack Durable Ltd exploded 8.58% to Rs 292.85. The stock was the fifth biggest gainer in 'A' group. On the BSE, 15.37 lakh shares were traded on the counter so far as against the average daily volumes of 68544 shares in the past one month.
India Cements Ltd, Tanla Platforms Ltd, Blue Jet Healthcare Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 27 April 2026.Cohance Lifesciences Ltd soared 19.99% to Rs 432.7 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 15.19 lakh shares were traded on the counter so far as against the average daily volumes of 4.86 lakh shares in the past one month. India Cements Ltd surged 12.10% to Rs 457.05. The stock was the second biggest gainer in 'A' group. On the BSE, 6.92 lakh shares were traded on the counter so far as against the average daily volumes of 10613 shares in the past one month. Tanla Platforms Ltd spiked 11.33% to Rs 541.5. The stock was the third biggest gainer in 'A' group. On the BSE, 4.43 lakh shares were traded on the counter so far as against the average daily volumes of 38325 shares in the past one month. Blue Jet Healthcare Ltd exploded 9.99% to Rs 443.75. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.05 lakh shares were traded on the counter so far as against the average daily volumes of 27090 shares in the past one month. Epack Durable Ltd rose 8.63% to Rs 253.1. The stock was the fifth biggest gainer in 'A' group. On the BSE, 52724 shares were traded on the counter so far as against the average daily volumes of 37732 shares in the past one month.
Vohra will succeed Vivek Sharma, who is stepping down as executive chairman for personal reasons. Sharma will continue with Cohance as an advisor for the next nine months to ensure a smooth transition. Vohra is one of the most accomplished leaders in the pharmaceutical industry. Over a career spanning more than three decades, he has led large, complex, global businesses through periods of strategic transformation while maintaining an unwavering focus on customers, quality and operational excellence. Most recently, as CEO and managing director of Cipla, Vohra led the company's transformation over the last decade to build a diversified global pharmaceutical enterprise. Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform. The company said the appointment reflects a deliberate, strategic decision taken by the board, to bring in a leader whose profile is specifically suited to the demands of Cohance's transformation and its next phase of growth. Commenting on appointment, Umang Vohra said, 'I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. It is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries for global pharmaceutical and life sciences customers. The company's consolidated net profit dropped 76% to Rs 36.72 crore on 19.5% decline in revenue from operations to Rs 544.55 crore in Q3 FY26 over Q3 FY25.
The board of Cohance Lifesciences at its meeting held on 27 April 2026 has approved the following: Noted the resignation of Vivek Sharma (DIN 08559495), as Executive Chairman and director of the Company with effect from 30 April 2026. Approved the appointment of Umang Vohra as Additional Director, designated as Chairman, and Group Chief Executive Officer with effect from 01 May 2026 and 20 May 2026 respectively.
Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales544.55676.23 -19 OPM %17.5135.10 - PBDT92.40248.13 -63 PBT45.46204.57 -78 NP36.72153.07 -76 Powered by Capital Market - Live
Cohance Lifesciences announced that the US FDA conducted an inspection at the Company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from 04 August 2025 to 12 August 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as 'Official Action Indicated (OAI)' and subsequently issued a Warning Letter for the said facility. The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter. The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%. Powered by Capital Market - Live
Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company's Nacharam formulation facility. The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same. The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025. Powered by Capital Market - Live
Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
Endurance Technologies Ltd, Time Technoplast Ltd, Jyoti CNC Automation Ltd and Lemon Tree Hotels Ltd are among the other losers in the BSE's 'A' group today, 13 November 2025.Cohance Lifesciences Ltd lost 8.38% to Rs 631.75 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.69 lakh shares were traded on the counter so far as against the average daily volumes of 67428 shares in the past one month.Endurance Technologies Ltd tumbled 7.67% to Rs 2692.6. The stock was the second biggest loser in 'A' group.On the BSE, 15663 shares were traded on the counter so far as against the average daily volumes of 7578 shares in the past one month.Time Technoplast Ltd crashed 6.14% to Rs 201. The stock was the third biggest loser in 'A' group.On the BSE, 2.33 lakh shares were traded on the counter so far as against the average daily volumes of 59774 shares in the past one month.Jyoti CNC Automation Ltd fell 5.61% to Rs 933.5. The stock was the fourth biggest loser in 'A' group.On the BSE, 45463 shares were traded on the counter so far as against the average daily volumes of 78342 shares in the past one month.Lemon Tree Hotels Ltd shed 4.85% to Rs 155.1. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.9 lakh shares were traded on the counter so far as against the average daily volumes of 1.34 lakh shares in the past one month.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.89%, vs industry avg of 9.86%
Over the last 5 years, market share decreased from 0.35% to 0.3%
Over the last 5 years, net income has grown at a yearly rate of -3.31%, vs industry avg of 19.69%